Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glyburide + insulin
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous
01
Overview
A combination therapy using glyburide (a sulfonylurea) with insulin for diabetes management. Glyburide is a second-generation sulfonylurea that works by stimulating insulin secretion from pancreatic beta cells through closure of ATP-sensitive potassium channels. This increases intracellular calcium concentration, which triggers insulin release. When combined with insulin therapy, this approach provides complementary mechanisms for blood glucose control, with insulin providing exogenous hormone replacement.
- Other names
- Glyburide and Insulin Combination Therapy
02
Targets
SUR1 (Sulfonylurea receptor 1)INSR (Insulin receptor)KATP channel (ATP-sensitive potassium channel)
Beyond the preview
Go deeper on glyburide + insulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glyburide + insulin.